Standard Biotools INC Form 4 insider transactions

Michael Egholm, President & CEO and a Director of Standard Biotools Inc., reported a transaction in 362,625 shares of common stock on August 3, 2026.

Standard BioTools Inc. amends its prior 8-K filing to include the Share and Asset Purchase Agreement for the sale of its mass cytometry business to Multiplex Bio Inc.

Standard BioTools Inc. announced the sale of its Mass Cytometry business to Multiplex Bio, a company led by advanced imaging industry veterans, with an expected closing by the end of 2026.

Standard BioTools Inc. announced the sale of its Mass Cytometry business to Multiplex Bio for $5 million and a $30 million buyout from Illumina, facilitating its merger with Treeline Biosciences.

Hanjoon Alex Kim, Chief Financial Officer of Standard Biotools Inc., reported a transaction in 202,476 shares of common stock on July 23, 2026.

Standard BioTools announced the filing of a registration statement for its merger with Treeline Biosciences, projecting over $900 million in combined cash and highlighting Treeline's clinical-stage pipeline.

Standard BioTools Inc. and Treeline Biosciences, Inc. have entered into a definitive merger agreement to combine in an all-stock transaction, creating a new entity named Treeline Biosciences.

Standard BioTools CFO Hanjoon Alex Kim reported the withholding of 18,871 shares to satisfy tax obligations related to RSU vesting.

SVP & Chief Business Officer Sean Mackay reported the withholding of 25,729 shares to satisfy tax obligations.

CEO Michael Egholm disposed of 97,626 shares of Standard BioTools to satisfy tax obligations related to RSU vesting.

Michael Egholm, President & CEO of Standard BioTools Inc., reported transactions involving common stock and stock options, including the acquisition of restricted stock units and the exercise of options.

Sean Mackay, SVP & Chief Business Officer of Standard BioTools Inc., reported a significant acquisition of common stock and stock options on March 20, 2026.

Standard BioTools CFO Hanjoon Alex Kim reports transactions involving restricted stock units and stock options, with a significant portion of RSUs vesting and some shares withheld for tax obligations.

Eli Casdin, a director and 10% owner of Standard BioTools Inc., elected to receive 52,991 Restricted Stock Units in lieu of $62,000 cash compensation for his board service, with vesting scheduled throughout 2026.

Standard BioTools Director Troy Cox acquired 57,264 Restricted Stock Units in lieu of cash compensation for board services, vesting quarterly in 2026.

Standard BioTools director Thomas D. Carey acquired 51,282 Restricted Stock Units in lieu of cash compensation, increasing his beneficial ownership.

STANDARD BIOTOOLS' President and CEO, Michael Egholm, disposed of 66,127 shares of common stock to cover tax withholding obligations related to RSU vesting.

Sean Mackay, SVP & Chief Business Officer of Standard BioTools Inc., disposed of 19,661 shares of common stock to cover tax withholding obligations.

Standard BioTools CFO Hanjoon Alex Kim reported a disposition of 12,740 common shares to cover tax obligations from restricted stock unit vesting.

Casdin Partners Master Fund and related entities increased their beneficial ownership in Standard BioTools Inc. through recent stock purchases.

Casdin Partners and affiliates significantly increased their stake in Standard BioTools Inc. through substantial share purchases in late November 2025.

STANDARD BIOTOOLS INC. CEO Michael Egholm disposed of 63,529 shares of common stock to cover tax liabilities related to RSU vesting.

Standard BioTools' Chief Financial Officer, Hanjoon Alex Kim, reported a routine disposition of 12,739 common shares to cover tax obligations from vested restricted stock units.

Standard BioTools' SVP & Chief Business Officer, Sean Mackay, disposed of 19,661 shares of common stock to cover tax obligations related to RSU vesting.

Casdin Partners Master Fund and affiliated entities increased their beneficial ownership in Standard BioTools Inc. through open market purchases totaling 1,075,000 shares.

Casdin Partners Master Fund, L.P. and affiliated entities increased their beneficial ownership in Standard BioTools Inc. through recent stock purchases.

Casdin Partners Master Fund and affiliated entities significantly increased their beneficial ownership in Standard BioTools Inc. through open market purchases in November 2025.

Casdin Partners Master Fund, L.P. acquired 100,000 shares of Standard BioTools Inc. common stock, increasing its beneficial ownership.

Casdin Partners Master Fund and related entities, including Director Eli Casdin, increased their beneficial ownership in Standard BioTools Inc. through recent stock purchases.

Casdin Partners Master Fund, L.P., a 10% owner and director, increased its beneficial ownership in Standard BioTools Inc. by acquiring 525,000 shares of common stock.